会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Trisubstituted 1,3,5,-triazine derivatives
    • 三取代1,3,5, - 三嗪衍生物
    • US06372729B1
    • 2002-04-16
    • US09634340
    • 2000-08-08
    • Frederik Frans Desiré DaeyaertBart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William Ludovici
    • Frederik Frans Desiré DaeyaertBart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William Ludovici
    • C07D25166
    • C07D251/42C07D251/50C07D251/52C07D251/66C07D251/70C07D403/12
    • This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0, 1, 2, 3 or 4; R1 and R2 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl; and each R4 independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is —X—R5 or —X-Alk-R6; wherein R5 and R6 each independently are indanyl, indolyl or phenyl; each of said indanyl, indolyl or phenyl may be substituted; and X is —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and pharmaceutical compositions comprising them.
    • 本发明涉及N-氧化物,其药学上可接受的加成盐和立体化学异构形式的化合物的用途,其中A是CH,CR 4或N; n为0,1,2,3或4; R1和R2各自独立地选自氢,羟基,C1-12烷基,C1-12烷氧基,C1-12烷基羰基,C1-12烷氧基羰基,芳基,氨基,单或二(C1-12烷基)氨基,单或二(C1- 12烷基)氨基羰基,其中各个上述C 1-12烷基可以任选地和各自独立地被取代; 或R 1和R 2可以一起形成吡咯烷基,哌啶基,吗啉基,叠氮基或单或二(C 1-12烷基)氨基C 1-4亚烷基; R3是氢,芳基,C1-6烷基羰基,任选取代的C 1-6烷基; 每个R 4独立地是羟基,卤素,C 1-6烷基,C 1-6烷氧基,氰基,氨基羰基,硝基,氨基,三卤代甲基或三卤代甲氧基; L是-X-R5或-X-Alk-R6; 其中R 5和R 6各自独立地为茚满基,吲哚基或苯基; 所述二氢化茚基,吲哚基或苯基中的每一个可以被取代; 并且X是-NR 3 - , - NH-NH - , - N = N - , - O - , - S - , - S(= O) - 或-S(= O) 芳基是任选取代的苯基; Het是任选取代的脂族或芳族杂环基; 用于制造用于治疗患有HIV(人类免疫缺陷病毒)感染的受试者的药物。 它还涉及作为式(I)化合物的亚组的新化合物,其制备方法和包含它们的药物组合物。
    • 9. 发明授权
    • Trisubstituted 1,3,5-triazine derivatives
    • 三取代1,3,5-三嗪衍生物
    • US06774235B2
    • 2004-08-10
    • US10067383
    • 2002-02-05
    • Frederik Frans Desiré DaeyaertBart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William Ludovici
    • Frederik Frans Desiré DaeyaertBart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald William Ludovici
    • C07D25166
    • C07D251/42C07D251/50C07D251/52C07D251/66C07D251/70C07D403/12
    • This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0, 1, 2, 3 or 4; R1 and R2 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl; and each R4 independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is —X—R5 or —X—Alk—R6; wherein R5 and R6 each independently are indanyl, indolyl or phenyl; each of said indanyl, indolyl or phenyl may be substituted; and X is —NR3—, —NH—NH—, —N═N—, —O—, —S —, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and pharmaceutical compositions comprising them.
    • 本发明涉及配制N-氧化物的化合物,其药学上可接受的加成盐和立体化学异构形式,其中A是CH,CR 4或N; n为0,1,2,3或4; R 1和R 2各自独立地选自氢,羟基,C 1-12烷基,C 1-12烷氧基,C 1-12烷基羰基,C 1-12烷氧基羰基,芳基,氨基,单或二(C 1-12烷基)氨基,单 - 或二(C 1-12烷基)氨基羰基,其中每个上述C 1-12烷基可以任选地和各自独立地被取代; 或R 1和R 2一起可以形成吡咯烷基,哌啶基,吗啉基,叠氮基或单或二(C 1-12烷基)氨基C 1-4亚烷基; R 3是氢,芳基,C 1-6烷基羰基,任选取代的C 1-6烷基; 每个R 4独立地是羟基,卤素,C 1-6烷基,C 1-6烷氧基,氰基,氨基羰基,硝基,氨基,三卤代甲基或三卤代甲氧基; L是-X-R 5或-X-Alk-R 6; 其中R 5和R 6各自独立地为茚满基,吲哚基或苯基; 所述二氢化茚基,吲哚基或苯基中的每一个可以被取代; 并且X是-NR 3 - , - NH-NH - , - N = N - , - O - , - S - , - S(= O) - 或-S(= O) 芳基是任选取代的苯基; Het是任选取代的脂族或芳族杂环基; 用于制造用于治疗患有HIV(人类免疫缺陷病毒)感染的受试者的药物。 它还涉及作为式(I)化合物的亚组的新化合物,其制备方法和包含它们的药物组合物。